title: Clinical outcome of patients with Wegener's granulomatosis treated with plasma exchange.
abstract: We report the clinical course of 29 patients with Wegener's granulomatosis (WG) treated with plasma exchange (PE) in Norway in the period from 1988 to 1999. Median follow-up was 41.5 months. The mean number of exchanges was 8.5 +/- 5.8 (range 2-32). Median serum creatinine concentration was 400 micromol/l (range 90-1,356) and 17 patients were dialysis dependent at presentation. Two- and five-year patient survival was 75 and 71%, respectively, and renal (ESRD-free) survival was 74 and 54%, respectively. Seven (50%) of the 14 patients alive in the dialysis group had discontinued dialysis within the first month, and 6 (50%) of 12 patients alive at follow-up had independent renal function. No patients, however, had normal serum creatinine concentration. Median time until development of ESRD for patients presenting with a need for dialysis was approximately 32 months. The development of ESRD in 79 patients treated with immunosuppression alone was significantly lower, but when adjusted for serum creatinine there was no difference between patients treated with or without PE. Although a considerable fraction of patients with WG and severe renal involvement regain independent renal function, few will have normal serum creatinine concentration at follow-up, despite the addition of PE as adjunctive therapy.
authors.affiliation: Department of Medicine, University Hospital of Trondheim; The Norwegian Kidney Register, Norway. knut.aasarod@medisin.ntnu.no
authors.forename: Knut
authors.initials: K
authors.lastname: Aasarød
authors.forename: Bjarne M
authors.initials: BM
authors.lastname: Iversen
authors.forename: Jens
authors.initials: J
authors.lastname: Hammerstrøm
authors.forename: Leif
authors.initials: L
authors.lastname: Bostad
authors.forename: Størker
authors.initials: S
authors.lastname: Jørstad
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D003401:Creatine / Q000097:blood; D005260:Female; D005500:Follow-Up Studies; D014890:Granulomatosis with Polyangiitis / Q000150:complications / Q000401:mortality / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D007676:Kidney Failure, Chronic / Q000209:etiology / Q000401:mortality / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009664:Norway; D010951:Plasma Exchange / Q000401:mortality / Q000592:standards; D006435:Renal Dialysis; D012189:Retrospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D007166:Immunosuppressive Agents; D003401:Creatine